After announcing a licensing deal for CR9114, a monoclonal antibody for influenza A and B from Janssen (NYSE:JNJ), Leyden Labs has won $140 million in Series B funding. Amsterdam-based Leyden Labs plans on developing an intranasal spray based on CR9114. Leading the round were Casdin Capital and GV (formerly Google Ventures). Leyden plans on using…
Leyden Labs licenses monoclonal antibody for influenza A and B from Janssen
Janssen (NYSE:JNJ) and Leyden Labs (Amsterdam) have signed a licensing agreement that gives the latter rights to develop CR9114, an antibody protecting against influenza A and B. Leyden hopes to commercialize CR9114 as a nasal spray. Under the terms of the deal, Janssen will get an upfront payment and could receive milestone payments tied to…